A multicenter study of survival after neoadjuvant radiotherapy/chemotherapy and esophagectomy for ypT0N0M0R0 esophageal cancer

Annals of Surgery

Volumn 252, Issue 5, 2010, Pages 744-748

  Vallbohmer D ^a   Hölscher, Arnulf H ^a   Demeester, S ^b   Demeester, T ^b   Salo, J ^c   Peters, J ^d   Lerut, T ^e   Swisher, S G ^f   Schroder W ^a   Bollschweiler, E ^a   Hofstetter, W ^f  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF ROCHESTER   (United States)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE FREE SURVIVAL; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; EUROPE; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SQUAMOUS CELL CARCINOMA; SURGICAL APPROACH; SURVIVAL RATE; THORACOTOMY; TREATMENT RESPONSE; UNITED STATES; ADVANCED CANCER; DISEASE SPECIFIC SURVIVAL; ESOPHAGUS CARCINOMA; HUMAN TISSUE; LOCALLY ADVANCED ESOPHAGUS CANCER; LYMPH NODE; SEX DIFFERENCE; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; EUROPE; FEMALE; HUMANS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; THORACOTOMY; TREATMENT OUTCOME; UNITED STATES;

EID: 78349276148     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181fb8dde     Document Type: Conference Paper

References (30)

1. Lerut T, Moons J, Coosemans W, et al. Multidisciplinary treatment ofadvanced cancer of the esophagus and gastroesophagealjunction: a European center's approach. Surg Oncol Clin N Am. 2008;17:485-502.
2. Urschel J, Vasan H. A meta-analysis ofrandomized controlled trials that com-pared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2003;185:538-543.
3. Kaklamanos IG, Walker GR, Ferry K, et al. Neoadjuvant treatment for re-sectable cancer of the esophagus and the gastroesophageal junction: a meta-analysis ofrandomizedclinicaltrials. Ann Surg Oncol. 2003;10:754-761.
4. Malthaner R, Wong R, Rumble R, et al. Neoadjuvant or adjuvant therapy for respectable esophageal cancer: a systematic review and meta-analysis. BMC Med. 2004;2:35.
5. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for esophageal cancer: asystematic review andmeta-analysis. Gut. 2004;53:925-930.
6. Greer S, Goodney P, Sutton J, et al. Neoadjuvant chemoradiotherapy for esophageal carcinoma: ameta-analysis. Surgery. 2005;137:172-177.
7. Gebski V, Burmeister B, Smithers BM, et al, for the Australian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234.
8. Schneider PM, Baldus SE, Metzger R, et al. Histomorphologic tumor regres-sion and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classifi-cation. Ann Surg. 2005;242:684-692.
9. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes ofresected esophageal cancer. Ann Surg. 2002;236:376-384.
10. Bollschweiler E, Hölscher AH, Metzger R. Histologic tumor type and the rate ofcomplete response after neoadjuvant therapy for esophageal cancer. Future Oncol (London). 2010;6:25-35.
11. Berger AC, Farma J, Scott WJ, et al. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol. 2005;23:4330-4337.
12. Rizk NP, Venkatraman E, Bains MS, et al. American Joint Committee on Cancer staging system does not accurately predict survival in patients re-ceiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol. 2007;25:507-512.
13. Donahue JM, Nichols FC, Li Z, et al. Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with en-hanced survival. Ann Thorac Surg. 2009;87:392-398.
14. Sobin LH, Wittekind C, eds. TNM Classification ofMalignant Tumours. 6th ed. New York: Wiley-Liss; 2002.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
16. Bollschweiler E. Benefits andlimitations ofKaplan-Meier calculations ofsur-vival chance in cancer surgery Langenbecks Arch Surg. 2003;388:239-244.
17. Earlam R, Cunha-Melo JR. Oesophageal squamous cell carcinoma, part I: a critical review ofsurgery Br J Surg. 1980;67:381-390.
18. Muller JM, Erasmi H, Stelzner M, et al. Surgical therapy of esophageal carcinoma. Br J Surg. 1990;77:845-857.
19. J Amieson GG, Mathew G,Ludemann R, et al. Postoperativemortalityfollowing esophagectomy and problems in reporting its rate. Br J Surg. 2004;91:943-947.
20. Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22:1-8.
21. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310-2317.
22. Bedenne L, Michel P, Bouche' O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160-1168.
23. Stah M, Wilke H, Lehmann N, et al. Long-term results of a phase III study investigating chemoradiation with and without surgery in locally ad-vanced squamous cell carcinoma (LA-SCC) of the esophagus. J Clin Oncol. 2008;26(suppl):abstr 4530.
24. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoad-juvant chemotherapy improves significantly the long term survival ofpatients withresectable esophageal squamous cell carcinoma. Cancer. 2001;91:2165-2174.
25. Brucher BL, Stein HJ, Zimmermann F, et al. Responders benefit from neoad-juvant radiochemotherapy in esophageal squamous cell carcinoma: results of aprospectivephase-IItrial. Eur J Surg Oncol. 2004;30:963-971.
26. Sloof GW. Response monitoring ofneoadjuvant therapy using CT, EUS, and FDG-PET. Best Pract Res Clin Gastroenterol. 2006;20: 941-957.
27. Schneider PM, Metzger R, Schaefer H et al. Response-evaluationby endoscopy rebiopsy and endoscopic ultrasound does not accurately predict histopatho-logic regression following neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248:902-908.
28. 18F]-Fluorodeoxyglucose-positron emission tomography for the assessment ofhistopathologic response and prognosis after completion ofneoadjuvant chemoradiation in esophageal cancer. Ann Surg. 2009;250:888-894.
29. Vallböhmer D, Brabender J, Metzger R, Hölscher AH. Genetics in the patho-genesis of esophageal cancer: possible predictive and prognostic factors. J Gastrointest Surg. 2010;14(suppl 1):S75-S80.
30. Krasna MJ, Jiao X, Mao YS, et al. Thoracoscopy/laparoscopy in the staging of esophageal cancer: Maryland experience. Surg Laparosc Endosc Percutan Tech. 2002;12:213-218.